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Asthma resistance to glucocorticoid treatment is a major health
problem with unclear etiology. Glucocorticoids inhibit adrenal andro-
gen production. However, androgens have potential benefits in
asthma. HSD3B1 encodes for 3β-hydroxysteroid dehydrogenase-1
(3β-HSD1), which catalyzes peripheral conversion from adrenal
dehydroepiandrosterone (DHEA) to potent androgens and has a
germline missense-encoding polymorphism. The adrenal restric-
tive HSD3B1(1245A) allele limits conversion, whereas the adrenal
permissive HSD3B1(1245C) allele increases DHEA metabolism to
potent androgens. In the Severe Asthma Research Program (SARP)
III cohort, we determined the association between DHEA-sulfate
and percentage predicted forced expiratory volume in 1 s (FEV1PP).
HSD3B1(1245) genotypes were assessed, and association between
adrenal restrictive and adrenal permissive alleles and FEV1PP in
patients with (GC) and without (noGC) daily oral glucocorticoid
treatment was determined (n = 318). Validation was performed
in a second cohort (SARP I&II; n = 184). DHEA-sulfate is associated
with FEV1PP and is suppressed with GC treatment. GC patients homo-
zygous for the adrenal restrictive genotype have lower FEV1PP com-
pared with noGC patients (54.3% vs. 75.1%; P < 0.001). In patients
with the homozygous adrenal permissive genotype, there was no
FEV1PP difference in GC vs. noGC patients (73.4% vs. 78.9%; P =
0.39). Results were independently confirmed: FEV1PP for homozygous
adrenal restrictive genotype in GC vs. noGC is 49.8 vs. 63.4 (P< 0.001),
and for homozygous adrenal permissive genotype, it is 66.7 vs. 67.7
(P = 0.92). The adrenal restrictive HSD3B1(1245) genotype is associ-
ated with GC resistance. This effect appears to be driven by GC sup-
pression of 3β-HSD1 substrate. Our results suggest opportunities for
prediction of GC resistance and pharmacologic intervention.
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Since their discovery and introduction into clinical medicineabout 70 y ago, glucocorticoids (GCs) have been recognized
as eliciting a systemic antiinflammatory response, and currently
play a major role in the treatment of severe asthma and other
inflammatory disease processes (1). However, unresponsiveness
to GC treatment is a major barrier to treatment of inflammatory
disease processes, and the underlying mechanisms of this clinical
entity have yet to be clearly elucidated (2). Management of GC-
unresponsive disease represents a significant challenge for the treat-
ment of asthma. Indeed, severe asthma is generally defined as
asthma that remains symptomatic despite high-dose inhaled GC
and/or systemic GC therapy (3).
Suppression of endogenous adrenal androgens and cortisol is a
known consequence of systemic GC treatment. Substantial evi-
dence suggests that stimulation of the androgen receptor (AR)
expressed in the lung could be beneficial in asthma. Androgens
inhibit human airway smooth muscle and fibroblast proliferation
(4–6), promote airway smooth muscle relaxation (7), and inhibit
both Th2 and Th1 inflammation in animal models of asthma (8,
9). Androgens are associated with better lung function in large
healthy cohorts (10, 11) and in asthma (12). Increasing circulating
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levels of adrenal and gonadal androgens in males and females
during adolescence are associated with improving asthma during
adolescence (12). However, the role of GC-induced androgen
suppression in the pathophysiology of severe, GC-resistant human
asthma is not established.
The androgen dehydroepiandrosterone (DHEA) and its sulfate
(DHEA-S) are secreted from the adrenal reticularis (13, 14), and
together are the most abundant steroid in circulation. However, its
function is not known. DHEA-S may have an immunomodulatory
effect, but clinical results have been inconsistent, possibly because
variations in DHEA-S metabolism are generally not taken into
account (15). In peripheral tissues, DHEA is metabolized by the
enzyme 3β-hydroxysteroid dehydrogenase-1 (3β-HSD1; encoded
by HSD3B1) to potent downstream androgens (e.g., testosterone
and dihydrotestosterone). A common missense-encoding variant
in HSD3B1, rs1047303 (c.1245C > A, p.T367N), regulates bio-
chemical function and clinical phenotypes. The HSD3B1(1245A)
allele encodes for an adrenal restrictive enzyme that limits con-
version from DHEA to downstream androgens, whereas the
HSD3B1(1245C) allele encodes for an adrenal permissive enzyme
that results in increased metabolic flux from DHEA to more
potent androgens (16). Multiple studies from the United States,
Japan, and Spain, now further confirmed in a phase 3 clinical
trial, clearly show that men with advanced prostate cancer
treated with castration who inherit the adrenal permissive 3β-
HSD1 enzyme, which confers more rapid conversion from
DHEA to potent androgens, have more rapid onset of androgen-
driven disease progression (17–22). These studies establish that
clear clinical phenotypes are associated with HSD3B1 genotypes
that biochemically confer fast and slow metabolic flux to potent
androgens. We hypothesized that the restrictive HSD3B1 geno-
type that disables DHEA-S conversion to potent androgens im-
pairs FEV1PP specifically when GC treatment suppresses adrenal
DHEA-S production, limiting substrate availability for 3β-HSD1
and possibly providing a mechanistic explanation for GC-resistant
severe asthma in patients with this genotype.
Severe Asthma Research Programs (SARP) are comprehen-
sive networks sponsored by the National Institutes of Health/
National Heart, Lung, and Blood Institute that aimed to char-
acterize and understand the pathobiology of severe asthma.
Here, we determined FEV1PP in the SARP III cohort for pa-
tients with asthma treated with (GC) and without (noGC) daily
oral GCs. Confirmatory studies were performed in patients with
severe asthma from the SARP I&II study.
Methods
Subjects. Individuals included in this analysis comprised a subset of 318
Caucasian (from 488 patients of all races) adults (aged >18 y) with asthma
enrolled in the SARP III study for whom genotyping data and pulmonary
function testing were available. We only included Caucasian patients in our
study because of the numbers of patients available for analysis and the
higher adrenal permissive HSD3B1(1245C) allele frequency of 30% to 40% in
Caucasians, as opposed to ∼8% in people of African descent.
SARP III, a network of 11 clinical research centers across the United States,
recruited 713 participants with asthma between 1 November 2012, and 1
October 2015. Of those 713 initially recruited participants with asthma, 526
were adults (aged >18 y), 60% had severe asthma as defined by the Euro-
pean Respiratory Society/American Thoracic Society criteria (3), and 17%
(21% of adult Caucasians) were chronically treated with chronic oral and/or
injectable GCs (i.e., systemic). The remaining 40% of patients with asthma
did not meet the criteria for severe asthma and were classified as having
nonsevere asthma. Among the 89 (17%) adult subjects treated with systemic
GCs in SARP III, 55 received daily oral GCs only, 15 received daily oral GCs
with additional GC injections, and 19 received intermittent GC injections
alone. In the group that received intermittent GC injections alone, the ma-
jority (14 participants) received 1 to 3 injections per year. The rest (5 subjects)
received more than 6 injections per year. While the suppressive effect of GCs
is predictable with chronic daily GC use, intermittent GC injections might
have an inconsistent effect on adrenal suppression, and accordingly, par-
ticipants receiving such therapy were excluded from the analysis. Patients
were also excluded if they were pregnant or breast-feeding during the ini-
tial characterization period, had a history of premature birth (<35 wk ges-
tation), or had a diagnosis of any other chronic pulmonary disorder. All
patients were not active smokers (past smokers should not have smoked
within a year or exceeded 10 pack-years of tobacco use if >30 y of age, or <5
pack-years if <30 y of age) and were required to have evidence of bronchial
hyperresponsiveness (defined as a PC20 methacholine value <16 mg/mL) or
reversible airflow obstruction, as evidenced by an increase in FEV1 of 12% or
greater after albuterol inhalation, ipratropium bromide inhalation, or both.
Spirometry was performed according to the American Thoracic Society/Euro-
pean Respiratory Society guidelines (23, 24). The 2012 Global Lung Initiative
standard reference equations were used to predict spirometric reference val-
ues (25). DHEA-S levels were analyzed at the University of Virginia Center for
Research in Reproduction Ligand Core Laboratory, using the Siemens Immulite
2000 immunoassay system, which has a lower limit of detection for DHEA-S of
15 μg/dL Information on SARP III network, protocol, and characterization
procedures have been published previously (26–28). All participants provided
written informed consent. The institutional review board at each center ap-
proved the study. The study is listed on ClinicalTrials.gov.
To replicate primary findings, 184 Caucasian participants (from a total of
263 of all races) with severe asthma were selected from the SARP I&II cohorts.
Similarly, SARP I&II is a National Institutes of Health/National Heart, Lung,
and Blood Institute-sponsored multicenter study that recruited patients with
asthma between 2001 and 2012 from 9 sites in the United States and 1 in the
United Kingdom. However, as compared with SARP III, patients with asthma
enrolled in SARP I&II were less likely to have severe asthma (40% vs. 60%)
(28–30). In contrast to SARP III, severe asthma was defined in SARP I&II
according to the initial ATS workshop definition of severe asthma (31).
Statistical Analysis. Whole-genome sequence of 1,888 patients enrolled in
SARP I, II, and III was released by the Trans-Omics for Precision Medicine
(TOPMed) program (https://www.nhlbiwgs.org/) in its genotype call sets
freeze 6a version. Whole-genome sequence with a read depth of 38× was
performed on blood DNA, using Illumina HiSeq X technology. The TOPMed
freeze 6a genotype call set includes 107,047 samples and 642M high-quality
variants genomewide, >7.6M coding variants, and >350,000 loss-of-function
variants. Genotype calling and quality control were performed by the In-
formatics Research Center, led by the University of Michigan.
Genotypes for variant rs1047303 (position chr1:119514623 [build
GRCh38.p12]) in SARP I, II, and III were extracted with PLINK2 (32, 33) (https://
www.cog-genomics.org/plink2). HSD3B1 genotypes were directly confirmed
in 28 patients, using a method previously validated with 100% match (17).
Student’s t test was used for 2 group comparisons of continuous normally
distributed variables. The means of the 3 different genotype groups were
compared using the ANOVA test. Pairwise comparisons were performed
using the Tukey–Kramer Honest Significant Differences (HSD) test. Other-
wise, Wilcoxon’s rank sum test or Kruskal–Wallis one-way ANOVA were used
when normality assumptions were not met. Categorical variables were
compared using a χ2 test. We assumed an additive model of inheritance, in
which predictor variables were an additive effect for the rs1047303 geno-
type (coded as the number of C alleles). Interaction terms were included
between rs1047303 genetic variants and daily oral GC as the dependent
variables of the prebronchodilator FEV1PP (pre-FEV1PP) post-FEV1PP. Models
were fit under the assumption of a normal distribution for FEV1PP. All sta-
tistical analyses were conducted with R, version 3.5.3 (R Project for Statistical
Computing, Vienna, Austria). A P value < 0.05 was considered statistically
significant because only one position was tested.
Data Availability. TOPMed genomic data and preexisting parent study phe-
notypic data are made available to the scientific community in study-specific
accessions in the database of Genotypes and Phenotypes (https://
www.ncbi.nlm.nih.gov/gap/).
Results
Baseline Characteristics. Baseline characteristics of Caucasian
SARP III participants with asthma and SARP I&II participants
with severe asthma are listed in Table 1. Aside from higher body
mass index (BMI) in participants with the CC compared with the
AA genotype enrolled in SARP III, patients with the AA, AC,
and CC genotypes had similar baseline characteristics. Other
than the CC genotype being associated with higher FEV1/FVC
ratio compared with AA and AC, all other characteristics were
not significantly different in participants with severe asthma
enrolled in SARP I, II, or III.
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Baseline DHEA-S and FEV1PP. FEV1PP was weakly associated with
serum DHEA-S in both men and women. In the SARP III co-
hort, the R2 (proportion of FEV1PP variability explained by
DHEA-S) was 0.04 for all races (n = 314; P < 0.001) and 0.04
(n = 203; P < 0.001) for Caucasians. Similarly, for severe asthma
in SARP I&II, the R2 was 0.13 (n = 271; P < 0.001) for all races
and 0.20 (n = 178; P < 0.001) in Caucasians (Fig. 1A and SI
Appendix, Table S1). This association appears to be driven by
patients with low DHEA-S (i.e., first quartile; SI Appendix, Fig.
S1). Strikingly, no women and very few men with DHEA-S levels
over 200 μg/dL in either cohort had a baseline FEV1PP of less
than 75% in SARP III.
DHEA-S Suppression Is Associated with Oral GC Use. Daily oral GC
therapy was commonly used in SARP III with median dose and
duration that did not differ among the 3 HSD3B1 genotypes. The
median duration was 12 mo for each of the 3 genotypes (P = 0.18
by Kruskal–Wallis test), and the median dose was 10 mg pred-
nisone (P = 0.74 by Kruskal–Wallis test). Overall, 22.6% (29% of
Caucasians) of adults with severe asthma enrolled in SARP III
were treated with daily oral GC therapy (26) (SI Appendix, Table
S2). Endogenous circulating cortisol declined significantly (P <
0.001) in patients receiving oral GCs, confirming both patient
compliance and adrenal suppression (SI Appendix, Fig. S2). As
expected, our analysis of DHEA-S from 314 adult participants
with asthma enrolled in SARP III showed significantly lower
plasma DHEA-S levels in patients treated with daily oral GC
therapy, as opposed to those not receiving daily oral GCs for
both men and women. Not surprisingly, DHEA-S decline occurs
in men and women (Fig. 1B), irrespective of HSD3B1(1245)
genotype (SI Appendix, Fig. S3), and there is no association be-
tween genotype and circulating testosterone (SI Appendix, Fig.
S4). Overall, daily GC therapy was associated with a 70% de-
crease in DHEA-S compared with no GC use in SARPIII and
SARPI/II (P < 0.001) (SI Appendix, Table S3). Circulating
DHEA also decreased by about 70% with GC therapy (SI Ap-
pendix, Fig. S5).
HSD3B1(1245) Genotype and GC Resistance. To test our hypothesis
that the HSD3B1(1245A) adrenal restrictive allele is specifically
associated with impaired lung function with GC treatment-
mediated adrenal suppression, lung function was compared in
318 GC and noGC Caucasian patients enrolled in SARP III for
whom HSD3B1(1245) genotype data were available. Statistical
comparisons of GC and noGC FEV1PP by HSD3B1(1245) ge-
notype, before and after bronchodilation (BD), are summarized
Table 1. Baseline characteristics comparing the 2 SARP cohorts, SARP III vs. SARP I&II, stratified by HSD3B1(1245) genotypes*
SARP III SARP I& II
AA AC CC P value AA AC CC P value
N 146 131 41 80 79 25
Age, y 49.5 ± 14.5 48.7 ± 13.8 47.8 ± 14.2 0.762 43.3 ± 11.2 46.3 ± 13.6 42.7 ± 13.7 0.26
Female sex, n (%) 92 (63.0) 80 (61.1) 31 (75.6) 0.230 46 (57.5) 47 (59.5) 20 (80.0) 0.11
BMI† 30.2 ± 6.2 31.8 ± 8.6 33.4 ± 9.8 0.038 30.3 ± 7.2 30.5 ± 7.5 29.9 ± 6.9 0.93
Daily oral GC therapy, n (%) 23 (15.8) 24 (18.3) 8 (19.5) 0.787 35 (43.8) 30 (38.0) 10 (40.0) 0.76
Severe asthma, n (%)‡ 82 (56.2) 77 (58.8) 20 (48.8) 0.530 80 (100) 79 (100) 25 (100)
FEV1/FVC ratio 0.84 ± 0.12 0.84 ± 0.12 0.90 ± 0.10 0.011 0.61 ± 0.13 0.64 ± 0.12 0.71 ± 0.11 0.026
Pre-FEV1, % of predicted value 71.8 ± 19.3 72.6 ± 21.8 77.9 ± 16.3 0.224 57.4 ± 19.2 61.1 ± 21.6 67.3 ± 23.7 0.09
Post-FEV1, % of predicted value 80.8 ± 20.2 80.3 ± 20.8 88.0 ± 16.5 0.083 73.5 ± 19.2 76.3 ± 20.7 79.3 ± 24.8 0.43
GC, daily oral glucocorticoid therapy; FVC, forced vital capacity; Post-, postbronchodilator; Pre-, prebronchodilator.
*Plus–minus values are means ± SD.
†The BMI is the weight in kilograms divided by the square of the height in meters.
‡Analyzed SARP I&II cohort includes patients with severe asthma.
Fig. 1. DHEA-S concentration is associated with FEV1PP and suppressed with daily systemic GC use. (A) In subjects with asthma, FEV1PP correlates significantly
with DHEA-S levels in both Caucasian men (blue circles; R2 = 0.15; P < 0.001) and women (open red circles; R2 = 0.03; P = 0.047). (B) Chronic daily GC use is
associated with DHEA-S suppression in SARP III in men and women.
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in Table 2, and graphical representations are presented in Fig. 2
A and B. Overall, pre- or post-FEV1PP was not correlated with
HSD3B1(1245) genotype in the noGC group. However, an in-
teraction was present between daily GC use and HSD3B1(1245)
genotype, suggesting that the effect of HSD3B1(1245) genotype
depends on daily GC use. In patients with asthma homozygous
for the HSD3B1(1245A) adrenal restrictive allele, pre-BD-
FEV1PP (Fig. 2A) for GC-treated individuals is significantly
worse than for noGC (54.3 vs. 75.1; P < 0.001). Post-BD-
FEV1PP for GC-treated individuals with the homozygous adre-
nal restrictive genotype (Fig. 2B) is similarly worse than noGC
(64.2 vs. 83.9; P < 0.001). In sharp contrast, for patients with
asthma homozygous for the HSD3B1(1245C) adrenal permissive
allele, the GC and noGC groups do not differ significantly for
either pre-BD-FEV1PP (73.4 vs. 78.9; P = 0.41) or post-BD
FEV1PP (83.1 vs. 89.2; P = 0.32). For patients with asthma
who inherit the heterozygous genotype, the association of poorer
outcomes in GC vs. noGC groups, although smaller in effect
compared with the homozygous adrenal restrictive genotype,
persists for pre-BD-FEV1PP (59.4 vs. 75.6; P = 0.001) and post-
BD-FEV1PP (67.7 vs. 83.2; P < 0.001). This relationship also holds
when the results were stratified by sex (SI Appendix, Fig. S6).
Results from the asthma control test similarly show that outcomes
in the GC group are worse for patients with asthma who inherit at
least one copy of the adrenal restrictiveHSD3B1(1245A) allele (SI
Appendix, Fig. S7), and that neutrophil counts significantly de-
crease in those who do not inherit the adrenal restrictive allele (SI
Appendix, Fig. S8).
To test the association between the HSD3B1 adrenal restric-
tive allele and lower FEV1PP with oral GC treatment in a dif-
ferent cohort, we assessed 184 Caucasian patients with severe
asthma in SARP I&II. Mirroring the results in SARP III, pa-
tients homozygous for the HSD3B1(1245A) adrenal restrictive
genotype in the GC group have significantly worse pre-BD-
FEV1PP (49.8 vs. 63.4; P < 0.001) and post-BD-FEV1PP (63.7
vs. 73.5; P < 0.05) than noGC (Fig. 2 C and D). Patients ho-
mozygous for the HSD3B1(1245C) adrenal permissive genotype
have pre-BD-FEV1PP and post-BD-FEV1PP that are statistically
indistinguishable between GC and noGC groups, effectively
replicating the findings in SARP III. FEV1PP for heterozygote
patients are again intermediate between AA (adrenal restrictive)
and CC (adrenal permissive) genotypes. Additional statistical
comparisons for SARP III and SARP I/II are shown in SI Ap-
pendix, Fig. S9. We acknowledge that sample size is a limitation
of our study.
The mechanisms by which androgens can benefit asthma have
been described in detail in animal models. In particular, andro-
gens directly inhibit airway inflammation (4, 8, 9, 15), airway
smooth muscle, and fibroblast proliferation (4–7). Consistent
with these data, we have recently shown that DHEA therapy
improves lung function in low-DHEA-S women (34). Moreover,
our additional analysis shows that all women in our study whose
serum DHEA-S increased by more than 300 μg/dL had an in-
crease in FEV1 (n = 8) compared with those who had less of an
increase in DHEA-S (P = 0.018 by Fisher’s exact test). Fur-
thermore, the plausibility of DHEA/DHEA-S benefit in asthma
is further supported by 3β-HSD1 expression in the human lung
(SI Appendix, Fig. S10). A model that summarizes the effect of
the association between HSD3B1(1245) genotype, DHEA-S
suppression with GC treatment and FEV1PP is shown in Fig. 3.
Discussion
Severe asthma is defined as asthma that remains symptomatic
and exacerbation-prone despite controlled high-dose inhaled
ICS or systemic steroid treatment in conjunction with a second
controller medication (3). Causes underlying severe asthma are
heterogeneous (28, 30, 35, 36), and many patients are refractory,
even to recently developed biological therapies (36). An aspect
of severe asthma that is not commonly considered is that sys-
temic GC therapy increases risk for low circulating levels of
androgens, particularly DHEA-S (37).
Our study supports a model in which HSD3B1(1245) geno-
types that confer less active conversion from adrenal precursors
to potent androgens in peripheral tissues leads to a physiologic
state of relative androgen deficiency that occurs specifically with
DHEA-S suppression that is a consequence of systemic GC
treatment. Strikingly, an HSD3B1(1245) allele-dose dependent
effect appears to be clear and occurs for pre-BD-FEV1PP and
post-BD-FEV1PP in both SARP III and SARP I&II.
In general, androgens require the AR to mediate much of their
physiologic effects. Potent AR stimulation from adrenal DHEA/
DHEA-S, which is available in circulation, requires enzymatic
conversion by 3β-HSD1 to testosterone and dihydrotestosterone,
which occurs in peripheral tissues. Given the variety of tissues in
which AR is expressed, the association observed in our study may
be attributable to androgen stimulation in several different cell
types. Androgens have many effects that could be beneficial for
the asthmatic airway. For example, DHEA-S inhibits human air-
way smooth muscle and fibroblast proliferation and may benefit
airway epithelial to mesenchymal transition (4–6). Both DHEA-S
Table 2. Comparison of maximum post-BD-FEV1% between patients treated with and without
daily oral GCs among the HSD3B1(1245) AA, AC, and CC genotypes*
SARP III SARP I & II
HSD3B1(1245) Genotype Not on GC On GC P value Not on GC On GC P value†
AA
n 123 23 45 35
Pre-FEV1, % of predicted value 75.1 ± 18.3 54.3 ± 15.3 <0.001 63.4 ± 18.8 49.8 ± 17.1 0.001
Post-FEV1, % of predicted value 83.9 ± 18.8 64.2 ± 19.6 < 0.001 73.5 ± 15.9 63.7 ± 18.4 0.024
AC
n 107 24 49 30
Pre-FEV1, % of predicted value 75.6 ± 21.2 59.4 ± 19.8 0.001 66.9 ± 22.3 54.3 ± 18.3 0.008
Post-FEV1, % of predicted value 83.2 ± 20.5 67.7 ± 17.9 <0.001 77.2 ± 20.8 67.8 ± 20.3 0.07
CC
n 33 8 15 10
Pre-FEV1, % of predicted value 78.9 ± 16.3 73.4 ± 16.6 0.41 67.7 ± 22.5 66.7 ± 26.6 0.92
Post-FEV1, % of predicted value 89.2 ± 17.0 83.1 ± 14.4 0.32 78.2 ± 22.3 80.7 ± 16.2 0.76
*Data are presented as mean ± SD for continuous variables and proportions or percentages for categorical
variables.
†P value comparing daily oral GC vs. no GC in each genotype group AA, AC, and CC.
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and testosterone promote airway smooth muscle relaxation (7).
Testosterone is associated with decreased Th2 and Th1 inflam-
mation in animal models of asthma (8, 9). Epidemiologically,
androgens are associated with better lung function in large healthy
cohorts (10, 11) and in disease (12). Increasing circulating levels of
adrenal and gonadal androgens in males and females during ad-
olescence are believed to be associated with improving asthma
during adolescence (12), and gonadal androgens in particular may be
associated with gender-based differences in asthma incidence and se-
verity in adulthood (12, 38–40). Notably, steroid metabolites down-
stream of DHEA-S are generated at the level of the target peripheral
tissue and are generally not appreciable in circulation (41, 42).
These data suggest that androgen depletion, whether circulating
and/or at the tissue level, could contribute to the pathophysiology
Fig. 3. A model that explains physiologic effects of HSD3B1 inheritance on FEV1PP in patients with severe asthma. GC treatment suppresses adrenal DHEA,
which may become a limiting substrate for 3β-HSD1, depending on HSD3B1 genotype. Adrenal permissive and adrenal restrictive alleles enable and limit
metabolic flux through 3β-HSD1 and recovery of airflow.
Fig. 2. The adrenal restrictive HSD3B1(1245A) allele is specifically associated with poor pulmonary function in GC-treated patients with severe asthma. In
Caucasian AA genotype patients with asthma enrolled in SARP III, baseline prebronchodilator FEV1PP (Pre-BD FEV1PP) (A) and postbronchodilator FEV1PP
(Post-BD FEV1PP) (B) is lower for those in the GC vs. no GC treatment groups. In contrast, for the CC genotype, there is no difference between GC and no GC
treatment groups. Lower Pre-BD FEV1PP (C) and Post-BD FEV1PP (D) for AA genotype patients receiving GC also occurs in Caucasian patients with severe
asthma enrolled in SARP I&II. Error bars indicate SEs.
Zein et al. PNAS | January 28, 2020 | vol. 117 | no. 4 | 2191
PH
YS
IO
LO
G
Y
of severe asthma and resistance to oral GC therapy. Our data
confirm that low DHEA-S levels in asthma are associated with low
lung function. However, we do not know whether this is a causal
relationship, whether low androgen levels are simply a marker as-
sociated with patients with low lung function on more GCs, or both.
We recently published a pilot study suggests that DHEA supple-
mentation in women with low DHEA-S improves FEV1 (34).
Recent studies of prostate cancer have shown that the adrenal
restrictiveHSD3B1(1245A) allele limits conversion of DHEA to more
potent androgens, whereas the adrenal permissive HSD3B1(1245C)
allele increases tissue production of potent androgens (16, 17).
The SARP studies provided an opportunity to study androgen
metabolism effects in severe asthma. We therefore hypothesized
that the restrictive allele, which impedes conversion from adre-
nal DHEA-S to testosterone and dihydrotestosterone, would be
associated with lower lung function in severe asthma when sys-
temic GCs are used and suppress substrate availability for 3β-
HSD1. Data were analyzed in the SARP III cohort, enriched for
severe asthma, and then validated in the patients with severe
asthma in the SARP I&II cohort and are strikingly consistent
with our hypothesis across both cohorts.
Limitations of this study include that it is restricted to Cau-
casian patients with asthma and the sample size, particularly for
patients with adrenal permissive HSD3B1(1245C) genotypes.
The low frequency of the adrenal permissiveHSD3B1(1245C) allele
in African-American subjects combined with the limited number of
subjects did not allow for a sufficiently powered analysis in non-
Caucasians. For example, only 1 African American participant
with CC genotype was enrolled in SARP III, and 2 others in
SARP I&II. The lower prevalence of the adrenal permissive C
allele in African Americans could contribute to higher severity
and risk from asthma, as well as GC resistance, in this patient
population. Similarly, none of the 27 adult Hispanic participants
with asthma enrolled in SARP III, and only 1 of the 34 adult
Hispanics enrolled in SARP I&II, respectively, carried the CC
genotype. Of note, the adrenal permissive allele frequency (i.e.,
the C allele) was 36% and 37% in adult Caucasian participants
with asthma enrolled in SARP III and severe asthma enrolled
SARP I&II. Those frequencies match the frequency reported for
Caucasians in the 1000 Genomes Project and suggest the ab-
sence of any deviation from Hardy–Weinberg Equilibrium.
In conclusion, we have identified a genetic determinant asso-
ciated with GC resistance and low lung function in asthma. Evi-
dence that the adrenal restrictive HSD3B1(1245A) allele, which
confers a lower level of prostate cancer adrenal androgen de-
pendence by preventing local conversion of DHEA to more po-
tent androgens, adversely affects lung function in GC-dependent
severe asthma suggests that androgens have a central role in the
pathophysiology of human severe asthma and response to systemic
GC treatment. Our data provide genetic evidence that comple-
ments epidemiological data regarding a benefit of androgens on
lung function. Our model is further supported by our data showing
a positive relationship between circulating adrenal DHEA-S levels
and lung function. Indeed, androgens cause airway smooth muscle
relaxation and prevent both remodeling and inflammation in an-
imal models of asthma. GC use suppresses endogenous androgen
production, preventing the beneficial effects of androgens in hu-
man asthma. These data suggest the possibility that HSD3B1 ge-
notype is predictive of which patients might benefit from systemic
GC therapy alone and, for those who are resistant, who would
benefit from androgen replacement in severe asthma.
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